CYB 003
Alternative Names: CYB-003; Deuterated psilocin - Cybin; Deuterated-Psilocin - CybinLatest Information Update: 03 Sep 2025
At a glance
- Originator Cybin
- Class Antidepressants; Antipsychotics; Behavioural disorder therapies; Drug withdrawal therapies; Small molecules; Tryptamines
- Mechanism of Action Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Major depressive disorder
- Discontinued Alcoholism; Psychiatric disorders
Most Recent Events
- 26 Aug 2025 TGA approves Clinical Trial Notification application for the phase III EMBRACE trial in Major depressive disorder (Adjunctive treatment) in Australia
- 18 Aug 2025 Discontinued - Preclinical for Alcoholism in Canada (PO) (Cybin pipeline, August 2025)
- 18 Aug 2025 Discontinued - Preclinical for Psychiatric disorders in Canada (PO) (Cybin pipeline, August 2025)